FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Antibe Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Antibe Therapeutics Inc. (ATBPF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisATBPF
ATBPF
Antibe Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ATBPF
Home🔹Stocks🔹Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATBPF•OTC

Antibe Therapeutics Inc.

ATBPF•OTC
Market cap
$11.43M
Sentiment

Your view on ATBPF

Mkt Cap
$11.43M
Sentiment
Your view
ATBPF
Antibe Therapeutics Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ATBPF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Antibe Therapeutics Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Daniel Marcel Legault
Headquarters
15 Prince Arthur Avenue, Toronto, ON, CA
Industry
Medical - Devices
Sector
Healthcare
CEO
Daniel Marcel Legault
Headquarters
15 Prince Arthur Avenue, Toronto, ON, CA
Description

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News